|
Dec 12
|
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
|
|
Dec 11
|
PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
|
|
Dec 4
|
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
|
|
Dec 1
|
Top Penny Stocks for Q4 2023
|
|
Nov 16
|
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript
|
|
Nov 16
|
Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
|
|
Nov 16
|
PAVmed Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 14
|
PAVmed Provides Business Update and Third Quarter Financial Results
|
|
Nov 13
|
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
|
|
Aug 24
|
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
|
|
Aug 22
|
PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why
|